Clinical Trials Logo

Hemoglobinopathy clinical trials

View clinical trials related to Hemoglobinopathy.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00968864 Terminated - Clinical trials for Acute Myeloid Leukemia

T-cell Depleted Alternative Donor Transplantation

Start date: August 2009
Phase: Phase 2
Study type: Interventional

The primary purpose is to determine the ability of CD34+ selection and T cell depletion using the CliniMACS® device to prevent severe acute graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from an alternative (unrelated and mismatched related) donor. The secondary objectives include evaluation of engraftment, immune recovery, and post-transplant infections. Patients requiring stem cell transplants for either malignant (cancerous) or non-malignant disease will be included in the study. The recipients will be grouped into one of two groups based on whether the donor is mismatched related (Cohort A) or unrelated (Cohort B). The patient will receive a conditioning regimen including chemotherapy drugs and/or total body irradiation based on the disease for which the transplant is performed.

NCT ID: NCT00040469 Terminated - Sickle Cell Anemia Clinical Trials

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Start date: August 2000
Phase: Phase 2
Study type: Interventional

The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.

NCT ID: NCT00040417 Terminated - Sickle Cell Anemia Clinical Trials

Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies

Start date: August 2000
Phase: Phase 2
Study type: Interventional

The major goal of this study is to determine the risks and benefits of stem cell transplants in combination with a newer, less toxic conditioning chemotherapy treatment in patients with severe sickle cell disease (SCD) or sickle hemoglobin variants (hemoglobin SC or hemoglobin SB0/+), or homozygous b0/+ thalassemia or severe B0/+ thalassemia variants. Participation in this project will be for one year, with follow up evaluations done every 6 months thereafter for 10 years or until participants are 18 years old.